Bayer (BAYN GY) announce that they remain confident in Asundexian's potential, adding that it's too early to comment on specific sales numbers

Bayer's statement reflects optimism regarding Asundexian's future performance, yet the cautious approach to specific sales figures suggests that there may be uncertainty about market reception and regulatory timelines.

Newsquawk StaffPublished On the live feed at 11 more headlines followed before this page went public
Newsquawk headlinesUTC

US EQUITY OPEN: Indices attempt to recoup recent losses, although AMZN is the latest mega-cap name to slide

US Treasury Secretary Bessent is expected to help Fed Chair Nominee Warsh "walk the tightrope" as the incoming Fed Chair – pursuing a “hawkish” approach to monetary policy while also catering to President Trump’s easy-money agenda, according to NY Post

Bayer (BAYN GY) announce that they remain confident in Asundexian's potential, adding that it's too early to comment on specific sales numbers

The EU is to reportedly push for trusted chips as part of a new drone strategy

Turkish Treasury Cash Balance (Jan) -246B (Prev. -333B)

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This sentiment could impact investor confidence, as traders may weigh this optimism against the broader context of competitive pressures and market dynamics in the pharmaceutical sector.

Related headlines

The whole workspace, free to try.

Try it free